The bottom line is this: The fact that some people on GLP-1 meds developed NAION doesnt mean the meds caused it
By secreting cytokines, cells of the immune system are able to modify the number and/or activity of other immune cells throughout the body
The free Gly-His-Lys tripeptide binds Cu(II) at a chelation pocket built from the histidine imidazole, the glycine N-terminal amino group, and adjacent backbone amides
Recent FDA reports, as of April 2025, have logged hundreds of adverse events linked to these products
Older people and those with less renal function might need to adjust their semaglutide dosage
Fatty acid side chain modifications Liraglutide The conjugation of a fatty acid chain to GLP-1 analogs significantly enhances their binding affinity to human serum albumin, thereby generating long-acting peptide formulations with improved pharmacokinetic profiles